Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

3 Jun 2008

Abstract excerpt

Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) delivers inhibitory signals to activated T cells. CTLA4 is constitutively expressed on regulatory CD4(+) T cells (Tregs), but its role in these cells remains unclear. CTLA4 blockade has been shown to induce antitumor immunity. In this study, we examined the effects of anti-CTLA4 antibody on the endogenous CD4(+) T cells in cancer patients. We show that CTLA4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18523152
DOI: 10.1182/blood-2007-11-125435

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashionPMID 18523152Read ↗

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.Semantic proximity Read ↗

Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferationSemantic proximity Read ↗

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4Semantic proximity Read ↗

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.Semantic proximity Read ↗

A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetSemantic proximity Read ↗

FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.Semantic proximity Read ↗

Targeting T regulatory (T reg ) cells in immunotherapy-resistant cancersSemantic proximity Read ↗

CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4Semantic proximity Read ↗

Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancerSemantic proximity Read ↗

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.Semantic proximity Read ↗

Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapySemantic proximity Read ↗

Overexpression of Regulatory T Cell-Related Markers (FOXP3, CTLA-4 and GITR) by Peripheral Blood Mononuclear Cells from Patients with Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.